Antitumor effect of anti-CCR4 antibody in head and neck cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26463042
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Nagasaki University (2016); Okayama University (2014-2015)
• Principal Investigator: DOMAE Shohei 長崎大学, 病院(歯学系), 講師 (70397892)
• Research Collaborator: KUNISADA Yuki ; TAKAKURA Hiroaki
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: CCR4分子 / 制御制T細胞 / 腫瘍浸潤リンパ球 / 頭頸部癌

Outline of Final Research Achievements

CCR4 expressing FoxP3+CD4 regulatory T cells (Treg) depletion using humanized anti-CCR4 monoclonal antibodies may enhance the host immune response against tumors. The current ongoing clinical trial investigates the use of humanized anti-human-CCR4 monoclonal antibody in the treatment of solid tumors. CCR4 expressing stroma infiltrating lymphocytes were detected in 32 of 42 (76.2%) head and neck cancer samples and were correlate with CCL22/MDC. CCR4 expressing tumor cells were detected in only 7 of 42 (16.7%) same samples. There was no markedly enhancement of antitumor effect by anti-CCR4 antibody in CCR4 expressing tumor cells.

Free Research Field

腫瘍免疫学